Welcome to our dedicated page for Beigene SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Beigene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Beigene's regulatory disclosures and financial reporting.
BeOne Medicines Ltd. (ONC) reported insider transactions by its President and COO. The reporting person sold 16,009 American Depositary Shares (ADS) on 11/12/2025 and 11/13/2025 at weighted average prices with trade ranges from $350.00 to $381.50, as detailed in the footnotes.
After these sales, the reporting person held 0 ADS directly. Beneficial ownership also includes 1,020,861 ordinary shares and 4,000 ADS held indirectly by spouse. Each ADS represents 13 ordinary shares. One footnote states that the ordinary share total includes 650 ordinary shares acquired under the company’s employee share purchase plan.
BeOne Medicines (ONC) reported insider activity by its SVP, General Counsel. On 11/12/2025, the officer exercised share options into 996 American Depositary Shares (ADS), which equals 12,948 Ordinary Shares (each ADS represents 13 Ordinary Shares), and sold 996 ADS pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
The ADS sales were executed at $348.75 (664 ADS) and $350 (332 ADS). Following these transactions, the reporting person beneficially owned 223,106 Ordinary Shares directly. The option exercises reflected exercise prices represented in Ordinary Shares of $14.96, $16.41, and $12.23, respectively.
BeOne Medicines (ONC) reported insider activity by its Chief Executive Officer and Director. The reporting person made two bona fide gifts of ordinary shares: 151,320 shares on 11/11/2025 and 858,533 shares on 11/12/2025, for a combined 1,009,853 shares, each at a stated price of $0 per footnote (gift). After these transactions, direct beneficial ownership stood at 6,441,041 ordinary shares.
The filing also lists indirect holdings, including 481,533 (P&O Trust), 7,722,480 (a grantor retained annuity trust), 28,204,115 (Oyler Investment LLC), 9,545,000 (Roth IRA), and 102,188 (The John Oyler Legacy Trust), as described in the footnotes with certain beneficial ownership disclaimers. No derivative securities were reported.
ONC: A shareholder filed a Form 144 notice to sell up to 6,009 shares of common stock, with an aggregate market value of $2,286,659.45. The filer lists Morgan Stanley Smith Barney LLC as broker, an approximate sale date of November 13, 2025, and the NASDAQ as the exchange.
The notice shows shares were acquired via restricted stock vesting under a registered plan on multiple dates. The table also reports 109,663,273 shares outstanding. Recent activity by the same seller over the past three months includes sales of 49,858 shares on August 13, 2025 for $15,162,320.35, 39,936 shares on August 14, 2025 for $12,180,813.46, and 10,000 shares on November 12, 2025 for $3,560,160.50.
ONC — Notice of proposed insider sale under Rule 144. A selling security holder filed a Form 144 to sell 10,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value $3,560,161.00. The shares are listed on NASDAQ, with an approximate sale date of 11/12/2025.
The filing lists prior acquisitions as restricted stock vesting under a registered plan across multiple dates, including 06/17/2023 (1,456 shares), 06/22/2023 (2,118), 06/05/2023 (4,291), 03/14/2024 (59), 09/15/2023 (52), 06/16/2023 (870), and 06/15/2024 (1,154). As context, shares outstanding were 109,663,273; this is a baseline figure, not the amount being offered.
The notice also reports sales in the past three months by Xiaobin Wu: 39,936 shares on 08/14/2025 for $12,180,813.46 and 49,858 shares on 08/13/2025 for $15,162,320.35.
BeOne Medicines (ONC): A director and Chair of the Scientific Advisory Board reported a bona fide gift of 424,073 ordinary shares on 11/07/2025 (Code G) at $0 pursuant to Rule 16b-5. Following the transaction, the director beneficially owned 4,582,601 shares directly.
Additional indirect holdings were reported with a disclaimer of beneficial ownership: 1,025,063 shares via a family trust, 3,953,100 shares via Wang Investment LLC, and 50 shares held by the spouse.
BeOne Medicines Ltd. (ONC) reported a profitable Q3. Total revenues were $1,412,284 for the three months ended September 30, 2025, driven by product revenue of $1,395,013. Net income was $124,841, a clear turnaround from a loss a year ago, as gross profit rose to $1,215,774 and operating income reached $163,114.
Cash generation was strong with year‑to‑date operating cash flow of $710,233, lifting cash and cash equivalents to $4,036,868. The company monetized future IMDELLTRA royalties, receiving $885,000 upfront from Royalty Pharma, recorded as a royalty sale liability with a 6.4% effective annual rate. BRUKINSA led product sales at $1,040,691 in the quarter, followed by TEVIMBRA at $190,623. Short‑term debt stood at $813,296 and long‑term debt at $139,571. Shares outstanding were 1,438,553,263 as of November 1, 2025.
BeOne Medicines Ltd. (ONC) filed an 8-K announcing its third-quarter 2025 results. The company reported that it announced financial results for the three months ended September 30, 2025, and furnished a related press release as Exhibit 99.1 titled “BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates.”
The information provided under Item 2.02 is being furnished and is not deemed “filed” under the Exchange Act. The filing also lists the company’s securities, including American Depositary Shares trading on Nasdaq under ONC, with each ADS representing 13 ordinary shares; the ordinary shares are listed on the Stock Exchange of Hong Kong under 06160.
BeOne Medicines Ltd. reporting person Lee Chan Henry (SVP, General Counsel) disclosed multiple transactions in American Depositary Shares (ADS) and options on 10/08/2025. The filing shows several sales under a Rule 10b5-1 plan adopted 05/14/2025, including weighted-average sale prices around $350 and $351. Offsetting purchases and transfers of ADS occurred the same day at prices between $159.03 and $213.32. After those transactions the reporting person holds 9,559 ADS equivalent and direct beneficial ownership in 223,106 ordinary shares. The report also discloses exercise/vesting schedules for outstanding options totaling 127,062 ordinary shares exercisable through 06/04/2034, with stated exercise prices shown in the filing.
BeOne Medicines Ltd. (BEIGF) filed a Form 144 notice reporting a proposed sale of 13,659 ADS through Morgan Stanley Smith Barney LLC on 10/08/2025, with an aggregate market value of $4,666,187.58 and 54,564,278 ADS outstanding. The filing shows the securities were acquired partly by exercise of stock options on 10/08/2025 (12,547 ADS, cash payment) and partly from restricted stock units on 07/29/2025 (1,112 ADS). The filer also disclosed three sales in the prior three months under Rule 10b5-1 and an individual sale: 09/10/2025 (10,006 ADS, $3,257,289.02), 08/13/2025 (9,342 ADS, $2,805,905.17), and 07/30/2025 (920 ADS, $280,232.74). The filer attests there is no undisclosed material adverse information and references potential reliance on a Rule 10b5-1 plan.